The research team also found that expression of the protein, known as PEA-15, is an independent indicator of a woman's prospects for surviving ovarian cancer, said senior author Naoto T. Ueno. An analysis of ovarian cancer tumours from 395 women showed those with high expression of the PEA-15 had a median survival time of 50.2 months compared with 33.5 months for women with low levels of the protein in their tumours.
"These findings provide a foundation for developing a PEA-15 targeted approach for ovarian cancer and for clarifying whether this protein is a novel biomarker that can predict patient outcomes," Ueno said.
A series of lab experiments showed that high expression of PEA-15 inhibits the growth of ovarian cancer cells by killing cells via autophagy, or self-cannibalisation, rather than by apoptosis. Removing PEA-15 from ovarian cancer cells led to a 115 percent increase in the number of cells compared with a control group of cells that still had the protein.
In apoptosis, defective cells die from self-induced damage to their nuclei and DNA complex. Autophagy kills when a cell entraps parts of its cytoplasm in membranes and digests the contents, leaving a cavity. When this goes on long enough, the cell essentially eats itself until it dies, its cytoplasm riddled with cavities.
The research team has found that the protein works to inhibit cancer in two distinct ways depending on its location in the cell. First, PEA-15 inhibits one of the prominent actors in the growth, differentiation and mobility of cells, a protein called extracellular signaling related kinase, or ERK. Activated ERK in the cell nucleus fuels cancer growth. The research team earlier found that PEA-15 binds to ERK in the nucleus and moves it out into the cytoplasm, preventing its growth effects.
Now they have found that PEA-15 in the cytoplasm induces autophagy in cancer cells, a second method of inhibiting cancer growth. "These two very different actions by PEA-15 are based on the location of the protein," Ueno said.
MEDICA.de; Source: University of Texas M. D. Anderson Cancer Center